ArticleAnnals of nuclear medicine2026
Integrating functional and volumetric assessments in
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIn this study, we aimed to evaluate the association between liver clearance values obtained from pre-treatment [⁹⁹ᵐTc]mebrofenin hepatobiliary scintigraphy and conventional liver function scores and biochemical parameters, and to perform an exploratory prognostic assessment of whether baseline clearance is associated with post-treatment outcomes, including overall survival, prior to ⁹⁰Y radioembolization. We also compared the functional assessment of the treatment region (based on mebrofenin uptake) with its anatomical CT volume (derived from [⁹⁹ᵐTc]macroaggregated albumin SPECT/CT) to determine the concordance between functional and volumetric data.
methodsPre-treatment [⁹⁹ᵐTc]mebrofenin and [⁹⁹ᵐTc]MAA scintigraphies were performed in 19 patients scheduled to receive Yttrium-90 (
resultsMebrofenin liver clearance showed significant (p < 0.05) negative correlations with pre- and post-treatment total and direct bilirubin levels and a positive correlation with post-treatment albumin. Clearance also demonstrated a strong inverse correlation with ALBI score (p < 0.05). Among biochemical changes, only the post-treatment change in direct bilirubin was significantly associated with clearance (p < 0.05). Functional and volumetric definitions of the treatment area showed strong correlation (ρ = 0.837, p < 0.001). In five patients with target ratio greater than 50% of liver volume, functional definition was not concordant with volumetric estimates. The difference in clearance values between patients surviving ≤ 6 months and > 6 months did not reach statistical significance. Among liver function scores, Child-Pugh exhibited the strongest, though non-significant, correlation with survival (ρ = - 0.407, p = 0.084).
conclusion[⁹⁹ᵐTc]mebrofenin scintigraphy correlated with both pre- and post-treatment biochemical liver function parameters. The functional definition of the treatment region assessed by scintigraphy and volumetric definition derived from SPECT/CT were also well concordant. The difference in clearance values between patients surviving ≤ 6 months and > 6 months did not reach statistical significance. Discrepancies between volumetric and functional definitions were observed in patients with extensive target volume (> 50% of liver volume). These preliminary findings suggest that [⁹⁹ᵐTc]mebrofenin scintigraphy may complement anatomical volumetry in the pretreatment assessment of functional liver reserve, but its potential role in individualized dosimetry requires confirmation in larger prospective studies.
Indexed as
Identifiers
42503047What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.